ALK I1171

CI-VAR-00001962Explore in graph →NP_004295.2:p.Ile1171ThrNM_004304.4:c.3512T>CClinVar 375888 CIViC 527

Curated evidence

Evidence by cancer (10 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–10 of 10 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Anaplastic Large Cell Lymphoma1
ALK I1171	Crizotinib	Predictive	D	Supports Resistance	—	submitted	EID4612 In an in vitro study, Karpas299CR cells expressing NPM-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK I1171T co-mutation, demonstrated resistance to crizotinib treatment compared… (full text at CIViC) PMID 24509625 · Zdzalik et al., 2014 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma9
ALK I1171	Alectinib	Predictive	C	Supports Resistance	4	accepted	EID1283 The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again … (full text at CIViC) PMID 25228534 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.